Your browser doesn't support javascript.
loading
Frontline combination of ponatinib and hyper-CVAD in Philadelphia chromosome-positive acute lymphoblastic leukemia: 80-months follow-up results.
Kantarjian, Hagop; Short, Nicholas J; Jain, Nitin; Sasaki, Koji; Huang, Xuelin; Haddad, Fadi G; Khouri, Issa; DiNardo, Courtney D; Pemmaraju, Naveen; Wierda, William; Garcia-Manero, Guillermo; Kebriaei, Partow; Garris, Rebecca; Loghavi, Sanam; Jorgensen, Jeffrey; Kwari, Monica; O'Brien, Susan; Ravandi, Farhad; Jabbour, Elias.
Afiliação
  • Kantarjian H; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jain N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Huang X; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Haddad FG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Khouri I; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Wierda W; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kebriaei P; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Garris R; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jorgensen J; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Kwari M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • O'Brien S; Chao Family Comprehensive Cancer Center, University of California Irvine, Orange, California, USA.
  • Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Am J Hematol ; 98(3): 493-501, 2023 03.
Article em En | MEDLINE | ID: mdl-36600670
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Doxorrubicina / Leucemia-Linfoma Linfoblástico de Células Precursoras Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Humans / Middle aged Idioma: En Revista: Am J Hematol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos